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ABSTRACT
Objective Fibrinogen is a target of autoimmune 
reactions in rheumatoid arthritis (RA). Fibrin(ogen) 
derivatives are involved in infl ammatory processes and 
the generation of a stable fi brin network is necessary 
for suffi cient infl ammation control. As the density 
and stability of fi brin networks depend on complex 
interactions between factor XIIIA (F13A) and fi brinogen 
genotypes, the authors studied whether these genotypes 
were related to C-reactive protein (CRP) levels during 
acute-phase reactions.
Methods Association between α-fi brinogen (FGA), 
β-fi brinogen (FGB) and F13A genotypes with CRP 
levels was tested in two cohorts with longitudinal 
CRP measurements. Discovery and replication cohorts 
consisted of 288 RA (913 observations) and 636 non-RA 
patients (2541 observations), respectively.
Results Genotype FGB −455G>A (rs1800790) was 
associated with CRP elevations (≥10 mg/l) in both cohorts 





<0.02; combined, OR 0.69, 
p<10−5/p
adj
=0.001). Genotype F13A 34VV (rs5985) 
was conditional for the association of FGB −455G>A 
with CRP as indicated by a clear restriction on F13A 
34VV individuals and a highly signifi cant heterogeneity 
between F13A 34VV and F13A 34L genotypes (p<10−5, 
p
adj
=0.001). In both cohorts, mean CRP levels signifi cantly 
declined with ascending numbers of FGB −455A alleles. 
Genotype FGA T312A (rs6050) exhibited opposite effects 
on CRP compared with FGB −455G>A. Again, this 
relation was dependent on F13A V34L genotype.
Conclusion Novel genetic determinants of CRP 
completely unrelated to previously known CRP regulators 
were identifi ed. Presumably, these haemostatic gene 
variants modulate infl ammation by infl uencing fi brin 
crosslinking. These fi ndings could give new perspectives 
on the genetic background of infl ammation control.
Fibrin crosslinking by factor XIII is of crucial impor-
tance not only for haemostasis but also for infl am-
mation control.1 Several aspects of infl ammatory 
processes including chemotaxis,2 3 cell adhesion 
and migration4–7 as well as the antimicrobial host 
defence1 8–10 are dependent on or at least signifi -
cantly infl uenced by fi brin(ogen) and its derivatives. 
In this context fi brin(ogen) functions as a modula-
tor of different types of cell–cell interactions.7 11 12 
Finally, fi brinogen is involved in the pathogenesis 
of rheumatoid arthritis (RA),13–15 and it is a tar-
get of anticitrullinated protein antibodies (ACPA), 
which characterise a clinically more severe subset 
of RA.16
The architecture of the fi brin gel is a major deter-
minant of clot rigidity and fi brinolysis resistance.17 
It depends on complex interactions between 
environmental and genetic factors.18 There are 
two well-characterised determinants of the fi brin 
gel architecture. On the one hand, the fi brin gel 
structure is critically infl uenced by fi brinogen lev-
els, which themselves exhibit a relevant genetic 
background.17–19 Therefore, variants located in 
the fi brinogen gene loci, for example, β-fi brinogen 
(FBG) −455G>A (rs1800790) or α-fi brinogen (FGA) 
T312A (rs6050), contribute to different amplitudes 
of fi brinogen level changes during acute-phase 
reactions.20–22 On the other hand, the factor XIII 
subunit A (F13A) genotype, particularly the variant 
F13A V34L (rs5985), plays a major role in decisively 
modulating the aforementioned relation between 
fi brinogen concentration and fi brin gel structure.18 
In the current study, we hypothesised that genetic 
variants of fi brinogen and F13A that are known to 
alter fi brin crosslinking could concomitantly infl u-
ence infl ammatory processes. For functional rea-
sons, the assessment of gene–gene interactions was 
a particular focus of the analyses.18 23
PATIENTS AND METHODS
Initially, the relation between fi brinogen and F13A 
genotypes on C-reactive protein (CRP) levels was 
assessed in a RA cohort. A replication of the results 
was achieved in a separate cohort under differing 
infl ammatory conditions (non-RA cohort). To allow 
for an observational assessment of genetic determi-
nants of CRP levels, which are infl uenced by differ-
ent factors, repeated measurement of CRP levels is 
necessary.24 25 Therefore, analyses were restricted 
to patients, for whom measurements of CRP levels 
on at least two independent times of presentation 
were available. Ethical approval for this study was 
obtained from the local ethics committee. Written 
informed consent was obtained from each patient. 
Data have been analysed anonymously.
RA cohort
The discovery cohort was derived from the 
RA study population described previously.26 Of 
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373 consecutive RA patients, all 288 patients who repeatedly 
presented in the Department of Rheumatology and Clinical 
Immunology (Berlin) between 2003 and 2008 (913 observations) 
were included. The patients fulfi lled the American College of 
Rheumatology criteria for classifi cation of RA.27 To account for 
potential confounders of CRP levels, sex, disease duration, HLA-
DRB1 shared epitope (SE), erosive joint disease,28 and the indi-
vidual treatment course characterised by cumulative therapy 
intensity26 were assessed and included in the analyses.
Non-RA cohort
The results of the RA cohort were replicated in an independent 
study population consisting of patients with no history of auto-
immune diseases (non-RA cohort). This cohort was enrolled 
during 2005 and 2007 at our haemostaseology outpatient depart-
ment (Charité – Universitätsmedizin Berlin). During this period 
1276 patients presented, and 636 patients (2541 observations), 
for whom measurements of CRP levels on at least two inde-
pendent times of presentation were available, were included. 
A considerable part of the non-RA cohort consisted of women 
followed during pregnancy because of a history of fetal loss, pla-
cental dysfunction or venous thromboembolism. Pregnancy is 
known as a mild proinfl ammatory condition with moderately 
elevated CRP levels.29 These are increased further in the case of 
disturbed placentation or other pregnancy complications.30 An 
association of CRP levels with the risk of venous thromboembo-
lism has been described previously.31 In the case of pregnancy, 
CRP levels have been determined regularly with each presenta-
tion. In all other cases, CRP measurement was prompted due to 
overt or suspected infl ammation.
Determination of fi brinogen, F13A and HLA-DRB1 
genotypes
FGB −455G>A (rs1800790), FGA T312A (rs6050) and F13A 
V34L (rs5985) genotypes were determined using allele-specifi c 
primer pairs, as described.32 33 SE was defi ned by HLA-DRB1 
alleles with the following constellation at the corresponding 
DRβ1 chain: 67Leu–69Glu–71Lys or Arg–74Ala–86Gly or Val. 
HLA-DRB1 typing was performed using standard techniques 
(Dynal, Oslo, Norway; GenoVision, Vienna, Austria; Protrans, 
Hockenheim, Germany).34
Autoantibody detection and measurement of CRP 
and D-dimer
ACPA were quantifi ed by a second-generation ELISA using 
a cut-off value of 25 arbitrary units per millilitre (Euro-
Diagnostica, Malmö, Sweden). Rheumatoid factor was quanti-
fi ed using an ELISA-based IgM-specifi c technique and a cut-off 
value of 24 IU per ml (DLD Diagnostika, Hamburg, Germany). 
Plasma CRP levels as well as D-dimer levels were quantifi ed by 
immunoturbidimetric methods standardised according to the 
International Federation of Clinical Chemistry and Laboratory 
Medicine (Roche Diagnostics, Mannheim, Germany).
Statistical analyses
For univariate analyses, OR and exact 95% CI were calculated. 
For calculations on allele–dose dependency, the corresponding 
wild type was used as a reference group, and a test for linear 
trend of the log odds (trend test) was performed. Power calcula-
tions have been performed on each cohort separately as well as 
on pooled cohorts. Based on a carrier frequency of FGB −455G>A 
and FGA 312A of approximately 0.40, statistical power for 
detecting an association strength of OR 1.75 was 62%, 92% 
and 99% for the RA cohort, the non-RA cohort and for pooled 
analyses, respectively. When considering stratifi cation for F13A 
V34L (carrier frequency of F13A 34L approximately 0.50) sta-
tistical power in respect of the fi brinogen genotypes and an 
association of OR 1.75 was: RA, 33%, non-RA, 64%, pooled, 
82%. For multivariate analyses, OR and 95% CI were calcu-
lated by logistic regression analyses. Analyses on the RA cohort 
were adjusted for disease duration (quartiles), sex, treatment 
intensity, erosive joint disease and SE. The adjustment model of 
analyses based on the non-RA cohort comprised age (quartiles), 
sex, ethnicity and ongoing pregnancy including 12 weeks after 
delivery. To evaluate for potential interactive effects, the corre-
sponding interaction terms were included in the logistic regres-
sion models as indicated (p for homogeneity).35 In cases of 
repeated measurements, for univariate as well as multivariate 
analyses, robust clustered estimates of variances were calcu-
lated (padj) to allow for intracluster correlation and to relax the 
requirement for independent observations.36
In addition to individual analysis of both cohorts, pooled anal-
yses on both cohorts have been included. In these combined 
analyses, OR and 95% CI were calculated as crude as well as 
Mantel–Haenszel point estimates and the homogeneity between 
both cohorts was assessed by Breslow–Day testing.
Non-parametric comparisons of CRP levels between different 
genotype constellations were performed by the Mann–Whitney 
U test or in the case of allele–dose dependency by the Cuzick 
non-parametric test for trend. Adjustment for non-independent 
observations within clusters was performed by rank order 
Somers’ D statistic (padj). Statistical analyses were performed 
using Stata statistical software 10.1 for Macintosh (StataCorp, 
College Station, USA). To consider multiple testing a Bonferroni’s 
corrected p<0.0125 was applied on the analyses of the discovery 
cohort.
Each polymorphism was analysed in respect of consistency 
with expected Hardy–Weinberg proportions by using Pearson 
χ2 tests. Marker–marker linkage disequilibrium was assessed 
using Lewontin’s D′ statistic and r2 correlation statistic using 
Haploview 4.1 (Cambridge, USA).37
Table 1 Clinical characteristics of the study populations
Characteristic RA cohort Non-RA cohort
No of cases 288 636
Total no of observations 913 2541
Women (%)  77.1   97.6
Age, median (IQR)* 51 (39–61) 32 (28–37)
Disease duration, median (IQR)   4.5 (1–10.9)
Erosive disease (%)  62.5
Presence of autoantibodies (%)
 ACPA  64.2
 RF  77.2
HLA-DRB1 shared epitope (%)
 1 copy  49.4
 2 copies  13.5
FGB −455G>A (%)
 1 copy  34.7   35.2
 2 copies   6.9    5.8
FGA T312A (%)
 1 copy  38.2   39.1
 2 copies   4.9    9.3
F13A V34L (%)
 1 copy  43.4   36.5
 2 copies   8.7    8.0
*RA patients: age at disease onset; non-RA patients: age at fi rst presentation.
ACPA, anticitrullinated protein antibodies; F13A, factor XIIIA; FGA, α-fi brinogen; FGB, 
β-fi brinogen; RA, rheumatoid arthritis; RF, rheumatoid factor.
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RESULTS
Clinical characteristics and genotype distributions
The clinical characteristics of both study populations are sum-
marised in table 1. In the RA cohort, 288 patients with a total 
of 913 observations (number of observations per patient: 2 
(n=17), 3 (n=205), 4 (n=66)) were included. The median inter-
val between consecutive CRP measurements was 68 days (IQR 
28–173 days). All patients of the RA cohort were of Caucasian 
origin. In the non-RA cohort, 636 patients with a total of 2541 
observations (observations per patient: 2 (n=201), 3 (n=114), 4 
(n=101), 5 (n=82), >5 (n=138)) were analysed. In this population, 
the median interval between consecutive CRP measurements 
was 36 days (IQR 31–46 days). The non-RA patients visited our 
haemostaseology unit because of recurrent fetal losses (45%), 
pregnancy complications (24%), and/or venous thromboem-
bolism (16%). Approximately 86% of the non-RA patients 
presented during the course of pregnancy, and 88% were of 
Caucasian origin.
All observed genotype distributions were consistent with 
Hardy–Weinberg equilibrium. There was no evidence for a 
linkage disequilibrium between F13A V34L and HLA-DRB1 SE 
(D′=0.062, r2=0.0030) as well as between FGA T312A and FGB 
−455G>A (D′=0.435, r2=0.02).
Plasma CRP levels depend on FGB −455G>A in RA patients: 
this effect is modulated by F13A V34L genotype
In the RA cohort, the presence of the FGB −455A allele was sig-
nifi cantly associated with a lower frequency of CRP elevations 
in univariate (p=0.0003, padj=0.01) as well as multivariate analy-
ses (p=0.0002, padj=0.01) (see supplementary table S1, avail-
able online only). Notably, a subanalysis among ACPA-positive 
RA patients usually characterised by enhanced infl ammatory 
activity showed a strong relation between FGB −455G>A and 
reduced odds for CRP elevations (176 patients, 557 observa-
tions) (p=0.0001, padj=0.003) (see supplementary table S1, avail-
able online only). It needs emphasis that the infl uence of FGB 
−455G>A on CRP elevations (≥10 mg/l) was signifi cantly allele–
dose dependent in univariate analyses and after adjustment for 
possible confounders (table 2).
In the whole study population, mean plasma CRP lev-
els declined with ascending numbers of FGB −455A alleles 
(p=0.0007, padj=0.01). This effect was most impressive in 
ACPA-positive RA. Here, mean CRP levels declined from 20.3 
mg/l (95% CI 15.6 to 25.1) for the FGB −455GG (wild-type) 
genotype to 13.2 mg/l (95% CI 10.4 to 16.1) and 8.6 mg/l (95% 
CI 3.3 to 13.8) in carriers of one and two FGB −455A alleles, 
respectively (p<10−5, padj=0.0006). In ACPA-negative RA a 
clear relation between FGB −455G>A and CRP could not be 
detected.
As there is strong evidence supporting a modulatory effect 
of the F13A V34L genotype on fi brin network formation,18 20 
we further tested whether the effect of FGB −455G>A on CRP 
elevations (≥10 mg/l) was interrelated with the F13A V34L geno-
type (table 2). Indeed, the relation between FGB −455A allele 
number and CRP was restricted to F13A 34VV genotype (138 
RA patients, 441 observations) in univariate and multivariate 




FGB −455GG FGB −455GA FGB −455AA Trend test
OR (reference) OR (95% CI) OR (95% CI) p/padj*
RA cohort
Total
 Univariate 1.0 0.64 (0.48 to 0.86) 0.52 (0.29 to 0.93) 0.0007/<0.015
 Multivariate 1.0 0.47 (0.30 to 0.74) 0.47 (0.16 to 1.38) 0.001/<0.03
F13A 34VV
 Univariate‡ 1.0 0.56 (0.36 to 0.86) 0.28 (0.09 to 0.83) 0.0008/<0.02
 Multivariate# 1.0 0.36 (0.19 to 0.71) …† <0.0008/0.01
F13A 34L
 Univariate‡ 1.0 0.73 (0.48 to 1.09) 0.71 (0.35 to 1.44) 0.12/0.24
 Multivariate§ 1.0 0.59 (0.32 to 1.10) 0.73 (0.21 to 2.61) 0.14/0.33
Non-RA cohort
Total
 Univariate 1.0 0.70 (0.54 to 0.91) 0.41 (0.21 to 0.79) 0.0004/<0.02
 Multivariate 1.0 0.72 (0.56 to 0.95) 0.42 (0.22 to 0.82) 0.001/0.02
F13A 34VV
 Univariate¶ 1.0 0.39 (0.27 to 0.58) 0.25 (0.10 to 0.62) <10−7/<0.0004
 Multivariate** 1.0 0.40 (0.28 to 0.59) 0.26 (0.10 to 0.64) <10−6/<0.0005
F13A 34L
 Univariate¶ 1.0 1.41 (0.95 to 2.09) 0.82 (0.32 to 2.13) 0.35/0.51
 Multivariate** 1.0 1.47 (0.99 to 2.18) 0.74 (0.28 to 1.94) 0.38/0.50
Analyses based on the RA cohort (288 RA patients, 913 observations) and the non-RA cohort (636 non-RA patients, 2541 
observations), respectively. Univariate and multivariate analyses (RA adjusted for disease duration, sex, erosive disease, shared 
epitope, therapy intensity; non-RA adjusted for sex, age, pregnancy, ethnicity) as well as trend tests across FGB −455A copy 
numbers are given.
*padj, p value after adjustment for non-independent observations within clusters.
†Ellipse indicates no CRP ≥10 mg/l in the FGB −455AA genotype.
‡p for homogeneity (RA, F13A 34VV vs F13A 34L)=0.12 (univariate).
§p for homogeneity (RA, F13A 34VV vs F13A 34L)=0.07 (multivariate).
¶p for homogeneity (non-RA, F13A 34VV vs F13A 34L)<10−5 (univariate).
**p for homogeneity (non-RA, F13A 34VV vs F13A 34L)<10−4 (multivariate).
CRP, C-reactive protein; F13A, factor XIIIA; FGB, β-fi brinogen; RA, rheumatoid arthritis.
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analysis, suggesting an interaction of these genotypes in mod-
ulating the extent of infl ammation. HLA-DRB1 SE did neither 
modulate the relation between FGB −455G>A and CRP nor was 
it related to CRP levels directly.
Finally, we tested whether fi brinogen and F13A genotypes 
were associated with erythrocyte sedimentation rate or mark-
ers of disease severity (ie, Steinbrocker score or disease activ-
ity score in 28 joints).38 In ACPA-positive RA, FGB −455G>A 
exhibited a non-signifi cant trend for lower erythrocyte sedimen-
tation rate levels (Mann–Whitney U test, p=0.19). There was no 
relation between these genotypes and the Steinbrocker score or 
disease activity score in 28 joints (data not shown).
Plasma CRP levels depend on FGB −455G>A in non-RA 
patients: this effect is modulated by F13A V34L genotype
In order to replicate the above fi ndings and to assess whether 
they were restricted to RA, we further tested the genetic mark-
ers in a non-RA cohort. In complete agreement with the results 
of the RA cohort, in the non-RA cohort the FGB −455G>A 
genotype exhibited a highly signifi cant trend towards lower 
CRP level categories (table 3), and again, this effect was clearly 
allele–dose dependent (table 2). The CRP-modulating effect 
of FGB −455G>A exhibited a striking restriction to carriers 
of the F13A 34VV (wild-type) genotype indicating a highly 
signifi cant interaction between FGB −455G>A and F13A V34L 
(p<10−5, table 2; p<10−6, table 3). The non-parametric com-
parison of CRP levels in dependence on the FGB −455A copy 
number (total, p<10−5, padj<0.01; F13A 34VV, p<10
−11, padj<10
-
4; F13A 34L carriers, p=0.40, padj=0.49) further corroborated 
the results.
Plasma CRP levels are infl uenced by FGA T312A in RA as well 
as in non-RA patients: this effect is restricted to F13A 34VV 
individuals
In F13A 34VV (wild-type) individuals, the FGB −455G>A 
genotype is negatively associated with CRP elevations in RA 
as well as in non-RA patients (see tables 2 and 3 as well as 
supplementary table S1, available online only). Fibrinogen lev-
els and fi brin gel formation are differentially infl uenced by the 
fi brinogen genotypes FGB −455G>A and FGA T312A.18 21 22 We 
therefore tested the association of FGA T312A with CRP in both 
cohorts. In F13A 34VV individuals, FGA T312A was positively 
associated with CRP elevations (≥10 mg/l) in the non-RA as 
well as the RA cohort. The OR per FGA 312A allele were nearly 
identical in both cohorts (non-RA, OR 1.50, p<0.002, padj<0.05; 
RA, OR 1.49, p=0.02, padj<0.09). The F13A 34VV genotype was 
conditional for this relation, ie, in F13A 34L-positive individuals 
an association between FGA T312A and CRP could be detected 
neither in the RA nor in the non-RA cohort. The results of these 
analyses were in complete accordance with those of non-para-
metric comparisons of CRP levels. In both cohorts, the mean 
CRP levels increased with each FGA 312A allele. This effect was 
especially pronounced in F13A 34VV-positive RA patients, in 
whom mean CRP levels increased from 12.3 mg/l (95% CI 9.7 
to 14.9) for the FGA 312TT (wild-type) genotype to 21.9 mg/l 
(95% CI 12.7 to 31.0) and 21.0 mg/l (95% CI 11.4 to 30.5) in 
carriers of one and two FGA 312A alleles, respectively (p<10−4, 
padj<0.01).
Association of FGB −455G>A and FGA T312A with CRP 
levels: pooled analysis on RA and non-RA cohorts
The relations of FGB −455G>A and FGA T312A genotypes on 
CRP elevations (≥10 mg/l) were assessed in a pooled analysis on 
both cohorts (table 4). Again, FGB −455G>A and FGA T312A 
exhibited oppositely directed associations with CRP eleva-
tions (≥10 mg/l). For both genotypes the relations signifi cantly 
differed between F13A 34VV and F13A 34L individuals, with 
the F13A 34VV genotype being conditional for the association. 
Importantly, there was no evidence of heterogeneity between 
the RA cohort and the non-RA cohort as indicated by Breslow–
Day tests for homogeneity (table 4). These fi ndings could also 
be confi rmed when analysing the relation of FGB −455G>A 
and FGA T312A to categorical CRP levels (≤5 mg/l, 5–10 mg/l, 
10–15 mg/l, >15 mg/l) (data not shown).
Table 3 Interactive infl uence of FGB −455G>A and F13A V34L genotype on plasma CRP level in the 
non-RA cohort
CRP (mg/l)
Carriage of FGB −455A versus FGB −455GG
Univariate Trend test Multivariate Trend test
OR (95% CI) p/padj* OR (95% CI) p/padj*
Total
 ≤5 1.0 (reference) 1.0 (reference)
 5–10 0.74 (0.60 to 0.90) 0.77 (0.62 to 0.94)
 10–15 0.71 (0.50 to 1.00) 0.75 (0.53 to 1.06)
 >15 0.52 (0.36 to 0.75) <10−5/0.009 0.54 (0.37 to 0.78) <0.0001/<0.02
F13A 34VV
 ≤5 1.0 (reference) 1.0 (reference)
 5–10 0.58 (0.45 to 0.77) 0.61 (0.46 to 0.81)
 10–15 0.39 (0.24 to 0.64) 0.41 (0.25 to 0.68)
 >15 0.27 (0.16 to 0.46) <10−10†/0.0001 0.28 (0.17 to 0.47) <10−9‡/<0.0002
F13A 34L
 ≤5 1.0 (reference) 1.0 (reference)
 5–10 0.97 (0.72 to 1.32) 0.99 (0.72 to 1.34)
 10–15 1.42 (0.86 to 2.35) 1.45 (0.87 to 2.41)
 >15 1.20 (0.69 to 2.10) 0.29†/0.63 1.23 (0.70 to 2.17) 0.35‡/0.56
Analyses based on 636 patients and 2541 observations. Results of univariate and multivariate analyses (adjusted for sex, age, 
pregnancy and ethnicity) as well as trend tests across ordinal CRP level categories are given.
*padj, p value after adjustment for non-independent observations within clusters.
†p for homogeneity (F13A 34VV vs F13A 34L)<10−6 (univariate).
‡p for homogeneity (F13A 34VV vs F13A 34L)<10−6 (multivariate).
CRP, C-reactive protein; F13A, factor XIIIA; FGB, β-fi brinogen; RA, rheumatoid arthritis.
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Relation of FGB −455G>A and FGA T312A genotypes to 
D-dimer levels in non-RA patients
We tested whether fi brinogen genotypes were associated with 
D-dimer levels in 607 non-RA patients (2069 observations). 
There was a signifi cant correlation between the FGB −455A 
copy number and lower D-dimer levels (p<0.04), which per-
sisted after adjusting for potential confounders (CRP, preg-
nancy, ethnicity, age and history of venous thromboembolism) 
(padj<0.04). The carriage of FGA 312A did not infl uence D-dimer 
levels signifi cantly.
DISCUSSION
In this report, we describe a modulating effect of fi brinogen 
genotypes on plasma CRP levels that is signifi cantly depen-
dent on the F13A V34L genotype. The involved genotypes are 
highly frequent and are known to exert an important effect on 
the haemostatic system predominantly by alteration of fi brin gel 
formation.17–19 While weak associations of these genotypes with 
atherothrombosis18 and venous thromboembolism39 have been 
described previously, there are no data indicating a relation to 
the risk of RA. The results identifi ed in a discovery cohort of RA 
patients were confi rmed in an independent replication cohort of 
non-RA patients. In both cohorts, the measures of association 
strength were of striking comparability and there was no statis-
tical evidence for heterogeneity between them. Replication in 
a non-RA cohort indicates that the relation between fi brinogen 
and F13A genotypes to CRP is independent of ACPA positivity 
and HLA-DRB1 SE-specifi c immune reactions.
As the data presented in our report are reminiscent of the 
relation between fi brinogen concentration and fi brin clot den-
sity in dependence on the F13A V34L genotype,18 regulation 
of fi brin crosslinking should be described in more detail. The 
fi brinogen level variation in the course of an acute-phase reac-
tion is infl uenced by the fi brinogen genotype.20 In this context, 
FGB −455G>A and FGA T312A favour higher and lower fi brino-
gen levels,  respectively.21 22 Fibrin crosslinking in turn is critically 
dependent on fi brinogen levels, and this relation is decisively 
modulated by the F13A V34L genotype.17 18 In the case of the 
F13A 34VV genotype, the density and stability of the fi brin net-
work strongly increases with increasing fi brinogen concentra-
tions. In contrast, the fi brin clot structure becomes gradually 
less dependent on fi brinogen levels with ascending numbers of 
F13A 34L alleles.18 In our study, the F13A 34VV genotype was 
also clearly conditional for the infl uence of FGB −455G>A and 
FGA T312A on CRP levels, and both fi brinogen genotypes were 
clearly inversely related to CRP. For example, the FGB −455G>A 
genotype, known to predispose to enhanced fi brinogen synthe-
sis during infl ammation,20 exhibited signifi cantly lower CRP 
levels (see tables 2–4 as well as supplementary table S1 avail-
able online only), while the opposite relation could be identifi ed 
for FGA T312A (table 4). These relations were restricted to the 
F13A 34VV genotype, ie, to individuals who are prone to form 
tight fi brin clot structures during phases of elevated fi brinogen 
levels and vice versa.18 The architecture of the fi brin gel matrix 
controls migratory processes.6 40 Differences in fi brin crosslink-
ing could thus be an explanation for the signifi cant interaction 
between fi brinogen and F13A genotypes on CRP levels, which 
we describe in this study. Briefl y, a predisposition to high fi brin 
clot densities during infl ammation seems to be related to a 
less intense CRP elevation (see supplementary fi gure S1, avail-
able online only). The relation between FGB −455G>A and 
lower D-dimer levels identifi ed in the non-RA cohort could 
be explained by increased fi brin clot density and consequently 
fi brinolysis resistance, and these data are completely compatible 
Table 4 Allele–dose-dependent association of FGB −455G>A and FGA T312A genotype on plasma 
CRP levels: pooled analyses on RA as well as non-RA cohort
 
CRP ≥10 mg/l
FGB −455G>A* FGA T312A†
Crude Pooled (M–H) Crude Pooled (M–H)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Total
 0 copy 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 1 copy 0.67 (0.56 to 0.82) 0.67 (0.55 to 0.82) 1.05 (0.87 to 1.26) 1.14 (0.94 to 1.38)
 2 copies 0.50 (0.33 to 0.76) 0.46 (0.30 to 0.72) 0.91 (0.63 to 1.31) 1.13 (0.78 to 1.65)
 p/padj trend <10
−5/0.001 <10−6/0.0006 1.0/1.0 0.23/0.40
 pBD 0.98 0.19
F13A 34VV
 0 copy 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 1 copy 0.46 (0.35 to 0.61) 0.45 (0.34 to 0.61) 1.31 (1.01 to 1.70) 1.49 (1.14 to 1.96)
 2 copies 0.25 (0.13 to 0.51) 0.26 (0.13 to 0.52) 1.64 (1.04 to 2.58) 2.11 (1.31 to 3.40)
 p/padj trend <10
−10/<0.00002 <10−9/<0.00002 0.008/0.07 0.0001/0.009
 pBD 0.32 0.98
F13A 34L
 0 copy 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 1 copy 1.01 (0.77 to 1.31) 1.02 (0.77 to 1.34) 0.83 (0.63 to 1.08) 0.83 (0.63 to 1.10)
 2 copies 0.93 (0.54 to 1.58) 0.75 (0.42 to 1.32) 0.38 (0.19 to 0.75) 0.42 (0.20 to 0.85)
 p/padj trend 0.88/0.92 0.59/0.70 <0.01/0.04 0.01/0.06
 pBD 0.08 0.25
Pooled analyses on RA (288 patients, 913 observation) and non-RA cohort (636 patients, 2541 observations). Crude as well as 
Mantel–Haenszel (M–H) point estimates of OR and 95% CI are given.
*p/padj for homogeneity (F13A 34VV vs F13A 34L) for FGB<10
−5/=0.001.
†p/padj for homogeneity (F13A 34VV vs F13A 34L) for FGA=0.0001/=0.006.
CRP, C-reactive protein; F13A, factor XIIIA; FGA, α-fi brinogen; FGB, β-fi brinogen; padj, p value after adjustment for non-
independent observations within clusters; pBD, Breslow–Day testing for homogeneity of OR between both cohorts; RA, 
rheumatoid arthritis.
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with this hypothesis. Alternatively, a genotype-dependent differ-
ential release of chemotactic or otherwise activating fi brin(ogen) 
derivatives2 10 41 could give another explanation of our fi ndings. 
The fact that the relation between FGB −455G>A and CRP is 
especially pronounced in ACPA-positive RA (see supplementary 
table S1, available online only) could be explained by increased 
infl ammatory activity in this RA subset.
Most if not all previously described genetic traits that affect 
CRP levels were located either within the CRP locus itself or 
in genes related to proinfl ammatory cytokine pathways.42–45 
Of note, previous studies did not provide any indication for a 
dependency of CRP levels on genetic variants of haemostatic 
factors. The fi brinogen variant FGB −148C>T (rs1800787), 
which is in strong linkage disequilibrium with FGB −455G>A, 
has been implicated in a reduction of tumour necrosis factor 
alpha (TNFα) and interleukin 6 responses after lipopolysaccha-
ride exposure—effects on CRP levels have not been described.46 
It is widely accepted that single-locus association studies have a 
high likelihood to fail in the identifi cation of risk factors, which 
exhibit signifi cant interactive effects.23 Therefore, published 
data, which until now were derived from locus-by-locus analy-
ses, were presumably incapable of elucidating interactive effects 
like those described in our report.
Measurement of CRP levels is an important and practical 
tool for monitoring disease activity in RA and a number of 
other infl ammatory diseases.47 Recent data indicate that in RA 
enhanced CRP levels serve as an independent prognostic fac-
tor for progressive joint damage independent of the underly-
ing treatment.48 49 Therefore, the data of our study could be of 
clinical value, as they could help in characterising patients with 
respect to their presumptive CRP response, thereby allowing for 
an adaptation of CRP-directed clinical decision models based on 
the patient’s genetic background.42
There are a few limitations of our study that should be rec-
ognised. First of all, our discovery cohort is small-sized, which 
results in a low statistical power, especially when considering 
analyses on stratifi ed data. Therefore, it is of importance that 
the results could be confi rmed in a larger replication cohort. 
Second, our study is primarily focused on CRP levels as a sur-
rogate marker of infl ammation. Further studies should include 
additional markers or mediators of infl ammation to get more 
insight into the mechanisms underlying our fi ndings. Finally, the 
described mechanisms that could potentially explain the results 
of our study are hypothetical. Even though the fi ndings on the 
relation between fi brinogen genotypes and D-dimer levels are 
compatible with the described hypothesis, a more sophisticated 
analysis of circulating fi brin(ogen) fragments could additionally 
support this assumption. Finally, future experimental studies 
should help to elucidate the way fi brinogen and F13A genotypes 
infl uence infl ammatory responses.
However, our fi ndings give perspectives to elucidate a pre-
viously unknown genetic mechanism of infl ammation control. 
Targeting the process of fi brin polymerisation and crosslinking 
could offer potential tools for pharmaceutical modulation of 
infl ammatory processes.
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